AI, liquidity, and cyclical growth are shaping today's top-heavy bull market. Early signs of cyclical growth are emerging.

Read here for 5 elite income stocks using the Total Portfolio Approach. Learn how active investing and high-conviction picks ...

Experts say FDA officials and doctors should treat hormone therapy like any other drug that has both benefits and risks, and remember that hormones aren’t the only options for treating menopausal ...

Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX₁₀₀ On Track for Early 2026Advancements in ...

U.S. net product revenue in third quarter of 2025 Continued U.S. product growth driven by direct-to-consumer (DTC) investments and real-world evidence, expected to accelerate with seamless prescribing ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Q3 2025 Earnings Call Transcript November 10, 2025 Compugen Ltd. beats earnings expectations. Reported EPS is $-0.07461, ...

R&D Pipeline -- IND-enabling activities for a PSMA-targeted ADC are on track for completion by year-end, further expanding the development portfolio.

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) Q3 2025 Earnings Call Transcript November 12, 2025 Atea Pharmaceuticals, Inc.

Q3 2025 Earnings Call Transcript November 12, 2025 PolyPid Ltd. beats earnings expectations. Reported EPS is $-0.37, ...

The huge checks Meta Platforms Inc. is writing to support its artificial intelligence ambitions are reminding some investors ...

Operator: Welcome to Tivic Health Systems third quarter 2025 financial results and operational update conference call. This ...